– USA, CA – Curate Biosciences, a key enabling technology company for cell therapy manufacturing, today announced the appointment of Mayo Pujols to its Board of Directors.
About Mayo Pujols
Mr. Pujols has worked in biopharmaceutical manufacturing for nearly thirty years including managing cell and gene therapy manufacturing operations for Novartis, Celgene, and Andelyn Biosciences, before joining Rocket as CTO and EVP in July of this year. His guidance will help Curate Biosciences through the initial commercialization of its Curate Cell Processing System in early 2023, as it capitalizes on the platform’s promise to broaden access to curative cell therapies.
While at Celgene, Mr. Pujols was VP of Global CAR-T Operations and Technology, where he was responsible for the global manufacturing scale-up of the cell therapy lisocabtagene maraleucel, now marketed by Bristol Myers Squibb. Later, as VP and Head of Global Cell and Gene Technical Development and Manufacturing for Novartis, he oversaw manufacturing and development of the pharma’s cell and gene therapy franchise.
“This is a great time to join Curate, as hundreds of companies are developing cell therapies and launching clinical trials,” said Mayo Pujols. “Potential partners are eagerly awaiting the commercial launch of the Curate® System for its ability to reduce the complexity, costs, and duration of manufacturing CAR-T and other curative cell therapies.”
About Curate Biosciences
Curate Biosciences is a life science company located in Carlsbad, CA, developing what standard cell processing technologies have failed to provide: the best quality starting material to dramatically reduce the total vein-to-vein cost. Curate Biosciences is advancing its platform technology – The Curate Cell Processing System – to allow a faster path to cleaner and larger quantities of starting cells, one of the significant bottlenecks in gene and cell therapies. The Curate Cell Processing System gently isolates leukocytes using Deterministic Cell Separation, an advanced, high-speed microfluidic technology that gently separates cells based on size. Optimized for processing apheresis and cell culture samples, the Curate platform obtains larger quantities of healthier leukocytes compared to other separation technologies.
For more information: https://www.curatebio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
